Skip to main content
. 2020 Sep 23;11:4809. doi: 10.1038/s41467-020-18396-7

Fig. 1. Cardiotoxicity of protein kinase inhibitors.

Fig. 1

a Approach to quantify relative clinical cardiotoxicity risk scores for kinase inhibitors from the FDA Adverse Event Reporting System (FAERS) database. b Reporting odds ratio (mean and 95% confidence interval of computed odds ratio) for cardiotoxicity across kinase inhibitors from FAERS. c Comparison of ranking derived from FAERS and WHO Pharmacovigilance data shows agreement. d Literature-reported in vitro and in vivo preclinical assays to predict KI-associated cardiotoxicity poorly correlated with clinical FAERS-derived risk scores for cardiotoxicity at clinical drug concentrations. e In vitro dose–response experiments for selected KIs for viability and mitochondrial stress poorly correlate with clinical FAERS-derived risk scores for cardiotoxicity. Source data are provided in source data file.